Welcome!

News Feed Item

Lumenis Ltd. Reports First Quarter Financial Results

Positive Momentum Continues With 9.5% Revenue Growth, Improved Profitability and Multiple New Product Approvals Across Business Portfolio

YOKNEAM, ISRAEL -- (Marketwired) -- 05/12/14 -- Lumenis Ltd. (NASDAQ: LMNS), the world's largest medical laser company for surgical, ophthalmic and aesthetic applications, today announced first quarter 2014 financial results.

First Quarter 2014 Summary:

  • Revenues of $65.8 million, up 9.5% year-over-year
  • Gross Margin of 52.6%, up 151 basis points year-over-year
  • Adjusted EBITDA of $4.8 million, up 37.9% year-over-year
  • Non-GAAP Net Income of $2.2 million, up 154.0% year-over-year. GAAP Net Loss of $3.1 million
  • $3.1 million net cash flow generated from ongoing business activities (1)

"We are pleased with our operating performance and financial results, highlighted by strong revenue growth of 9.5% and continued improvement in gross margins and profitability," said Tzipi Ozer-Armon, Chief Executive Officer. "I am particularly excited about the introduction of our new LightSheer® line and the Lumenis Pulse™120H, our advanced innovative Urology platform, that we believe will enhance our future growth as they increase our addressable market and improve our position in the industry. The proceeds from our IPO have further solidified our balance sheet and provided capital to further invest in our business."

First Quarter 2014 Financial Results
Total revenue in the first quarter of 2014 was $65.8 million, an increase of 9.5% compared to revenue of $60.1 million last year. Product revenue was $52.6 million, an increase of 11.5% compared to product revenue of $47.2 million last year. Total revenue growth was driven primarily by our two largest business segments, Surgical and Aesthetic and product revenues posted growth in all geographical regions, with particular strength in Europe, the Middle East and Africa (EMEA) and Asia Pacific (APAC).

First quarter 2014 gross profit was $34.6 million, an increase of $3.9 million, or 12.7%, compared to $30.7 million last year. First quarter 2014 gross margin was 52.6%, compared to 51.1% last year, an increase of 151 basis points.

On a GAAP Basis:

First quarter 2014 GAAP operating expenses were $33.0 million, an increase of $4.1 million, or 14%, compared to operating expenses of $28.9 million last year. The increase was mainly driven by investment in sales and marketing, increased investment in R&D as well as one-time IPO related expenses.

First quarter 2014 GAAP operating income was $1.6 million, a decrease of $0.1 million, or 8.7%, compared to GAAP operating income of $1.7 million last year. First quarter 2014 GAAP operating margin was 2.4%, compared to 2.9% last year.

First quarter 2014 GAAP net loss was $3.1 million, a decrease of $3.1 million, compared to near breakeven last year. GAAP net loss per share was $0.10 in the first quarter of 2014 compared to breakeven last year, based on 30.9 million and 29.0 million diluted shares outstanding respectively.

On a Non-GAAP Basis:

First quarter of 2014, Non-GAAP results exclude a $4.9 million one-time items related to our IPO. Of these expenses, $4.0 million were a one-time payment to Bank Hapoalim B.M. triggered by the completion of the Company's IPO, as defined in the Company's loan agreement with Bank Hapoalim B.M. Non-GAAP results also exclude stock based compensation expense of approximately $0.8 million and the revaluation income of embedded derivative of approximately $0.3 million.

First quarter 2014 Non-GAAP operating income was $3.3 million, an increase of $1.0 million, or 44.0%, compared to Non-GAAP operating income of $2.3 million last year. First quarter 2014 Non-GAAP operating margin was 5.0%, compared to 3.8% last year.

First quarter 2014 Adjusted EBITDA was $4.8 million, an increase of $1.3 million, or 37.9%, compared to $3.5 million last year. Adjusted EBITDA margin was 7.4% compared to 5.8% last year.

First quarter 2014 Non-GAAP net income was $2.2 million, an increase of $1.3 million, or 154.0%, compared to $0.9 million last year. Non-GAAP net income per diluted share was $0.07 in the first quarter of 2014 compared to $0.03 last year based on 32.4 million and 29.6 million diluted shares outstanding respectively.

Cash and cash equivalents were $114.9 million as of March 31, 2014 compared to $42.8 million as of December 31, 2013. This increase is primarily due to the successful completion of our initial public offering in March 2014.

New Product Introductions and Approvals

  • Surgical: In March, the Company received FDA clearance and CE mark for the "Lumenis Pulse 120H", the new high-power Holmium platform, offers an unrivaled combination of power, speed, safety and versatility. This single platform provides a superior offering for four major urological procedures -- Enucleation, Flexible Ureteroscopy, Vaporization and PCNL. The Company is planning over 30 physician training courses worldwide this year to drive the adoption of this product.

  • Aesthetics: The Company announced two new additions to the Lightsheer® family of hair removal products. The "Lightsheer® Infinity™" is Lumenis' most advanced laser hair removal system which is an optimal solution for all skin types, including tanned and dark skin types. The "Lightsheer® Desire™" is a compact, portable and upgradable system with an advanced user interface, which allows easy treatment delegation and a quick learning curve. Both systems are up to 75 percent faster than other currently available devices and have received very positive feedback from physicians and patients in recent American and European tradeshows.

  • Ophthalmic: The Company received both an FDA approval and a Japanese MHLW clearance for the Array™ LaserLink™ pattern scanning device for multi-spot laser photocoagulation at the end of calendar 2013, and began commercialization in Japan in the first quarter. The early market response in Japan for this new scanning device has been very positive, where Ophthalmologists have expressed enthusiasm particularly about the shorter treatment time and reduced patient discomfort.

Full Year 2014 Financial Guidance

For the full year ended December 31, 2014, we expect to report:

  • Revenue in a range of $282 to $285 million, representing an increase of 6.3% to 7.4% year-over-year
  • Adjusted EBITDA in a range of $28.6 to $30.2 million, representing an increase of 10% to 16% year-over-year
  • Non-GAAP Net Income in a range of $17.6 to $19.2 million, representing an increase of 18% to 29% year-over-year, and Non-GAAP EPS of $0.50 to $0.54

(1): Net cash flow generated from ongoing business activities includes cash flow from operating and investing activities as well as foreign currency translation adjustments related to cash and cash equivalents in the period.

Conference Call

Lumenis will host a conference call on Monday, May 12, 2014 at 5:00 p.m. Eastern Time to discuss its first quarter 2014 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial the following numbers approximately ten minutes prior to the start of the call: 888-389-5988 for callers based in the United States, 1-80-924-5906 for callers based in Israel and 719-325-2432 for callers based in all other countries. The reservation code for the call is 9972028. Please dial in approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Lumenis' website at http://www.lumenis.com. The replay will be available on the Company's website for approximately 90 days.

About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare. For more information visit: www.lumenis.com

Forward-Looking Statements

Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.


                                LUMENIS LTD.
                                (Unaudited)

                     Consolidated Revenue, by Geography
---------------------------------------------------------------------------
                                       Three         Three
                                    Months Ended  Months Ended
                                     March 31,     March 31,     % Change
                                   ------------- -------------
                                                                Year-over-
U.S. dollars in thousands               2014          2013         Year
                                   ------------- ------------- ------------
Revenues:
  Americas                         $      21,545 $      20,579          4.7%
  APAC                                    18,755        16,610         12.9%
  EMEA                                    14,260        11,403         25.1%
  Japan                                   11,244        11,519        -2.4*%
                                   ------------- ------------- ------------
Total Revenues                     $      65,804 $      60,111          9.5%
(*) +2% on a constant currency basis


                      Consolidated Revenue, by Segment
---------------------------------------------------------------------------
                                       Three         Three
                                    Months Ended  Months Ended
                                     March 31,     March 31,     % Change
                                   ------------- -------------
                                                                Year-over-
U.S. dollars in thousands               2014          2013         Year
                                   ------------- ------------- ------------
Revenues:
  Aesthetic                        $      26,564 $      21,611         22.9%
  Surgical                                24,345        23,202          4.9%
  Ophthalmic                              14,895        15,298       -2.6**%
                                   ------------- ------------- ------------
Total Revenues                     $      65,804 $      60,111          9.5%
(**) -0.8% on a constant currency basis




                                LUMENIS LTD.
              Condensed Consolidated Statements of Operations
                                (Unaudited)
                                                   Three          Three
                                                Months Ended   Months Ended
                                                 March 31,      March 31,
                                               -------------  -------------
U.S. dollars in thousands (except per share         2014           2013
 data)
                                               -------------  -------------

Revenues:

  Products                                     $      52,606  $      47,198
  Services                                            13,198         12,913
                                               -------------  -------------
Total Revenues                                 $      65,804  $      60,111

Cost of Revenues
  Products                                            24,688         22,457
  Services                                             6,529          6,968
                                               -------------  -------------
Total Cost of Revenues                                31,217         29,425

                                               -------------  -------------
Gross Profit                                   $      34,587  $      30,686

Operating Expenses:
  Research and development, net                        6,268          5,052
  Selling and marketing                               20,861         19,010
  General and administrative (*)                       5,872          4,886
                                               -------------  -------------
Total Operating Expenses                              33,001         28,948

                                               -------------  -------------
Operating Income                               $       1,586  $       1,738

  Financial expenses, net                                 59            966
  IPO related Bank Cash Fee                            4,000              -

                                               -------------  -------------
Total Financial Expenses                               4,059            966

                                               -------------  -------------
Pre-Tax Income (Loss)                          $      (2,473) $         772

  Tax expenses                                           664            814

                                               -------------  -------------
Net Loss                                       $      (3,137) $         (42)
                                               =============  =============

Net loss per common shares:
  Basic                                        $       (0.10) $       (0.00)
                                               =============  =============

  Diluted                                      $       (0.10) $       (0.00)
                                               =============  =============

Weighted-average common shares outstanding:
  Basic                                           30,865,773     28,981,858
                                               =============  =============

  Diluted                                         30,865,773     28,981,858
                                               =============  =============

(*) General and administrative expenses for the three months ended March
 31, 2014, include IPO related compensation expenses in the amount of $880.






                                LUMENIS LTD.
                    CONDENSED CONSOLIDATED BALANCE SHEETS


                                                     March 31,  December 31,
                                                    ----------- ------------
(U.S. dollars in thousands)                             2014        2013
                                                    ----------- ------------
                                                    (Unaudited)
ASSETS
Cash and cash equivalents                           $   114,869 $     42,811
Trade receivables (net of allowance for doubtful
 accounts of $2,484 and $2,690 at March 31, 2014
 and December 31, 2013 respectively)                     40,896       42,867
Prepaid Expenses and other receivables                    9,770       10,194
Inventories                                              38,058       36,075
                                                    ----------- ------------
Total Current Assets                                    203,593      131,947

Finished goods used in operations, net                    4,756        4,793
Property and equipment, net                               8,795        8,094
Goodwill                                                 50,217       50,217
Severance pay fund                                        3,452        3,875
Other assets                                              7,213        7,519
                                                    ----------- ------------
Total Long-Term Assets                                   74,433       74,498
                                                    ----------- ------------
TOTAL ASSETS                                        $   278,026 $    206,445
                                                    =========== ============

LIABILITIES AND SHAREHOLDERS' EQUITY
Restructured debt                                        17,335       17,493
Trade payables                                           27,095       24,553
Other accounts payable and accrued expenses              43,185       39,413
Deferred revenues and customers advances                 21,312       19,057
                                                    ----------- ------------
Total Current Liabilities                               108,927      100,516

Restructured debt                                        51,489       52,024
Accrued post-employment benefits                          8,428        8,906
Deferred revenues                                         7,765        8,144
Other liabilities                                        19,090       19,155
                                                    ----------- ------------
Total Long-Term Liabilities                              86,772       88,229
                                                    ----------- ------------

TOTAL LIABILITIES                                       195,699      188,745
                                                    =========== ============

SHAREHOLDERS' EQUITY                                     82,327       17,700
                                                    ----------- ------------

                                                    ----------- ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          $   278,026 $    206,445
                                                    =========== ============





                                LUMENIS LTD.
                   Consolidated Statements of Cash Flows
                                (Unaudited)
                                                     Three         Three
                                                 Months Ended  Months Ended
                                                   March 31,     March 31,
                                                 ------------  ------------
(U.S. dollars in thousands)                          2014          2013
                                                 ------------  ------------

Cash flows from operating activities:
Net Loss                                         $     (3,137) $        (42)
Adjustments required to reconcile loss to net
 cash provided by operating activities:
Depreciation and amortization                           1,588         1,252
Compensation related to employees stock option
 plan                                                     794           405
Adjustments related to restructured debt                3,127          (733)
Revaluation of financial assets and other, net            296           215
Deferred income taxes, net                                591           655

Decrease (increase) in trade receivables, net           2,094        (3,172)
Decrease (increase) in inventories and finished
 goods used in operations                              (2,700)          864
Increase in prepaid expenses and other
 receivables                                             (653)          (29)
Increase in trade payables                              1,797         4,695
Increase (decrease) in other accounts payables
 and accrued expenses (including short and long-
 term deferred revenues and customer advances)            435           (65)
Increase in accrued post-employment benefits,
 net                                                       38           146
Increase (decrease) in other long term
 liabilities                                             (267)          499

                                                 ------------  ------------
Net cash provided by operating activities               4,003         4,690

Cash flows from investing activities:
Purchase of property and equipment                       (919)         (638)
                                                 ------------  ------------
Net cash used in investing activities                    (919)         (638)

Cash flows from financing activities:
Issuance of share capital, net                         68,852             -
Proceeds from exercise of share options                    35            12
                                                 ------------  ------------
Net cash provided by financing activities              68,887            12

Foreign currency translation adjustments related
 to Cash and cash equivalents                              87          (321)

Increase in cash and cash equivalents                  72,058         3,743
Cash and cash equivalents at the beginning of
 the period                                            42,811        27,103

Cash and cash equivalents at the end of the
 period                                          $    114,869  $     30,846
                                                 ============  ============

Supplemental information and disclosures of non-
 cash investing and financing activities:
  Issuance costs by utilizing prepayments        $        311             -
                                                 ============  ============
  Accrued issuance costs                         $      1,557             -
                                                 ============  ============
  Purchase of property and equipment             $        650             -
                                                 ============  ============


Use of Non-GAAP Financial Measures:

The Company has presented the following non-GAAP financial measures in this press release: non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, adjusted EBITDA and adjusted EBITDA margin. The Company defines non-GAAP operating income as its reported operating income (GAAP) excluding stock-compensation expense, one-time charges and other non-recurring operating costs and expenses. The Company defines adjusted EBITDA as its non-GAAP net income before financial expenses, net, taxes on income, and excluding depreciation and amortization expense. The Company defines its non-GAAP net income to exclude non-recurring or unusual expenses, specifically, in the first quarter of 2014: (i.) stock based compensation of $0.8 million, (ii.) IPO compensation-related expenses of approximately $0.9 million, (iii.) one-time payment to Bank Hapoalim of approximately $4.0 million triggered by the completion of the Company's IPO and (iv.) embedded derivative revaluation income of approximately $0.3 million in the first quarter of fiscal year 2014.


                                LUMENIS LTD.
                 Reconciliation of GAAP to Non-GAAP results
                                (Unaudited)
                                                     Three         Three
                                                 Months Ended  Months Ended
                                                   March 31,     March 31,
                                                 ------------  ------------
(U.S. dollars in thousands)                          2014          2013
                                                 ------------  ------------
Reconciliation from GAAP Gross Profit to Non-GAAP Gross Profit

GAAP Gross Profit                                $     34,587  $     30,686
  Stock-based compensation                                 46            38
                                                 ------------  ------------
Non-GAAP Gross Profit                            $     34,633  $     30,724
                                                 ============  ============

Reconciliation from GAAP Operating Income to Non-GAAP Operating Income and
 Adjusted EBITDA

GAAP Operating Income                            $      1,586  $      1,738
  Total stock-based compensation                          793           405
  Legal settlements                                         -           120
  IPO compensation expenses                               880             -
                                                 ------------  ------------
Non-GAAP Operating Income                               3,259         2,263
  Depreciation and Amortization                         1,588         1,252
                                                 ------------  ------------
Adjusted EBITDA                                  $      4,847  $      3,515
                                                 ============  ============

Reconciliation from GAAP Net Loss to Non-GAAP Net Income

GAAP Net Loss                                    $     (3,137) $        (42)
  Total stock-based compensation                          793           405
  Legal settlements                                         -           120
  IPO compensation expenses                               880             -
  One-time payment to Bank Hapoalim BM                  4,000             -
  Revaluation of embedded derivative and other
   non- recurring items                                  (339)          382
                                                 ------------  ------------
Non-GAAP Net Income                              $      2,197  $        865
                                                 ============  ============

Reconciliation from GAAP Diluted Net Loss Per Common Share to Non-GAAP
 Diluted Net Income Per Common Share

GAAP diluted net loss per common share           $      (0.10) $      (0.00)
                                                 ============  ============
Non-GAAP diluted net income per common share     $       0.07  $       0.03
                                                 ============  ============

Shares used in computing GAAP diluted net income
 per common share                                  30,865,773    28,981,858
                                                 ============  ============

Shares used in computing Non-GAAP diluted net
 income per common share                           32,356,961    29,604,696
                                                 ============  ============


More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that Ayehu will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara California. Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infras...
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex software systems for startups and enterprises. Since 2009 it has grown from a small group of passionate engineers and business...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 21st Int\ernational Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their ...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
SYS-CON Events announced today that Cloud Academy named "Bronze Sponsor" of 21st International Cloud Expo which will take place October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara, CA. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud com...
We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.